ArticlePloS one2016
Effects of Ranolazine on Astrocytes and Neurons in Primary Culture.
Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 33 citations in OpenAlex.
- Trim47 protects against hypoxic-ischaemic brain injury in neonatal rats by reducing brain microvascular endothelial inflammation and BBB disruption by interacting with ZO1.Acta pharmacologica Sinica · 2026Article
- Effects of Ranolazine on Vascular Adrenergic Receptors in Rabbit Aorta.International journal of medical sciences · 2026Article
- Dual roles of lactate and lactylation modification in the nervous system: neuroprotection and neuroinjury.Frontiers in aging neuroscience · 2026Review
- Glioprotective Effects of Ilex paraguariensis Standardized Extract Through Nrf2 Activation and NF-κB Suppression in lipopolysaccharide-treated Astrocytes.Neurochemical research · 2025Article
- Key copper homeostasis genes and inflammatory mechanisms in ischemic stroke: A bioinformatics and experimental study.Functional & integrative genomics · 2025Article
- Effects of ranolazine on angiogenesis and oxidant-antioxidant balance: an in vivo experimental model study.Scientific reports · 2025Article
- Association between ranolazine therapy and cognitive decline in elderly patients with ischemic heart disease.Frontiers in pharmacology · 2025Article
- Unraveling the pharmacological and therapeutic potential of Ranolazine beyond antianginal drug use: a new insight.Experimental biology and medicine (Maywood, N.J.) · 2025Review
- Effects of GS-967, GS-6615 and ranolazine on the responses of the rabbit aorta to adrenergic nerve stimulation.Frontiers in physiology · 2025Article
- The Anti-Apoptotic Effect of Ranolazine on Cerebral Protection during Cardiopulmonary Bypass and Carotid Artery Surgery.Acta Cardiologica Sinica · 2024Article
- Improvement of Vascular Insulin Sensitivity by Ranolazine.International journal of molecular sciences · 2023Article
- Functions of Astrocytes under Normal Conditions and after a Brain Disease.International journal of molecular sciences · 2023Review
- Neuroprotective effect of ranolazine improves behavioral discrepancies in a rat model of scopolamine-induced dementia.Frontiers in neuroscience · 2023Article
- Ranolazine Attenuates Brain Inflammation in a Rat Model of Type 2 Diabetes.International journal of molecular sciences · 2022Article
- Facilitation of Insulin Effects by Ranolazine in Astrocytes in Primary Culture.International journal of molecular sciences · 2022Article
- Ranolazine: An Old Drug with Emerging Potential; Lessons from Pre-Clinical and Clinical Investigations for Possible Repositioning.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Contemporary approach to understand and manage COVID-19-related arrhythmia.The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology · 2021Review
- Downregulating carnitine palmitoyl transferase 1 affects disease progression in the SOD1 G93A mouse model of ALS.Communications biology · 2021Article
- COVID-19-related arrhythmias and the possible effects of ranolazine.Medical hypotheses · 2021Article
- Glycolysis and Fatty Acid Oxidation Inhibition Improves Survival in Glioblastoma.Frontiers in oncology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ranolazine (Rn) is an antianginal agent used for the treatment of chronic angina pectoris when angina is not adequately controlled by other drugs. Rn also acts in the central nervous system and it has been proposed for the treatment of pain and epileptic disorders. Under the hypothesis that ranolazine could act as a neuroprotective drug, we studied its effects on astrocytes and neurons in primary culture. We incubated rat astrocytes and neurons in primary cultures for 24 hours with Rn (10-7, 10-6 and 10-5 M). Cell viability and proliferation were measured using trypan blue exclusion assay, MTT conversion assay and LDH release assay. Apoptosis was determined by Caspase 3 activity assay. The effects of Rn on pro-inflammatory mediators IL-β and TNF-α was determined by ELISA technique, and protein expression levels of Smac/Diablo, PPAR-γ, Mn-SOD and Cu/Zn-SOD by western blot technique. In cultured astrocytes, Rn significantly increased cell viability and proliferation at any concentration tested, and decreased LDH leakage, Smac/Diablo expression and Caspase 3 activity indicating less cell death. Rn also increased anti-inflammatory PPAR-γ protein expression and reduced pro-inflammatory proteins IL-1 β and TNFα levels. Furthermore, antioxidant proteins Cu/Zn-SOD and Mn-SOD significantly increased after Rn addition in cultured astrocytes. Conversely, Rn did not exert any effect on cultured neurons. In conclusion, Rn could act as a neuroprotective drug in the central nervous system by promoting astrocyte viability, preventing necrosis and apoptosis, inhibiting inflammatory phenomena and inducing anti-inflammatory and antioxidant agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.